Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...

Vertex Pharmaceuticals Inc.’s new non-opioid painkiller is being placed on a tier that means it might be costlier than other pain treatments on UnitedHealth Group Inc.’s approved drug lists.

Google (GOOG) expands its partnership with Reddit (RDDT) to enhance AI capabilities and improve search relevance with Vertex ...

To that end, Florida Tech has relaunched the underutilized Center for Advanced Manufacturing and Innovative Design as Vertex, a new "applied innovation hub." Rather than function as a traditional ...

Vertex Pharmaceuticals Incorporated ... CASGEVY for the treatment of sickle cell disease and transfusion-dependent beta thalassemia; JOURNAVX for the treatment of acute pain in adults; VX-522 ...

Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $502.92, signifying a +1.51% move from its prior day's close. We recently published a list of the 11 Best Pharma Stocks to Buy ...

But the first iOS 18.4 public beta is finally here, and it brings a lot of big and small changes for iPhone. Here’s what’s new in today’s release. The only big new AI features we’re still ...

Apple’s newest beta cycle has finally arrived. Today the company has released macOS Sequoia 15.4 beta 1 alongside a variety of other updates for developers. First macOS 15.4 beta brings ...

Last week, Apple launched their developer beta for iOS 18.4. The update brings fresh changes to iOS, including Priority Notifications, a new Genmoji button, and additional supported languages.

Apple today seeded the first betas of upcoming iOS 18.4 and iPadOS 18.4 updates to developers for testing purposes, with the software coming a month after Apple released iOS 18.3 and iPadOS 18.3 ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...